A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Pancreas Cancer
Interventions: DRUG: SN132D
Sponsor: Spago Nanomedical AB
Collaborators: CTC Clinical Trial Consultants AB|Antaros Medical